The Norwegian Institute of Public Health

Our goal is to improve public health through promotion of good health and prevention of disease. The Norwegian Institute of Public Health is a national center of excellence in the areas of epidemiology, mental health, control of infectious diseases, environmental medicine, forensic toxicology and drug abuse. Our vision: A healthier society. Our motto: Knowledge for better public health.

EARNEST: A subproject in the Norwegian Mother and Child Cohort Study

What are the effects of early nutrition on illness in adults? The Norwegian Institute of Public Health will investigate these effects as part of the EU project EARNEST. The Norwegian contribution to EARNEST is a subproject in the Norwegian Mother and Child Cohort Study (MoBa). 


More... [12.02.2007]

Scientific fraud: No data handed out from the Norwegian Institute of Public Health

Last week fraud was revealed in a scientific paper published in the Lancet in October 2005. A scientist from the Radium Hospital has admitted that he has fabricated the data on which the article is based. This issue is currently under investigation. In the article it is indicated that data from Norwegian health surveys, which is part of the Cohort of Norway (CONOR), and data from the Norwegian Prescription Registry have been used. This is not correct. No data files have been handed out from the Norwegian Institute of Public Health to the scientist in question nor to any of his collaborators in this connection. Read more about CONOR on our website.


[17.01.2006]

CONOR - data from several regional health studies

CONOR is a collection of health data and blood samples from several Norwegian health surveys. When the data collection is over, CONOR will be a unique database with health data and biological samples of about 200 000 individuals. The purpose of CONOR is investigating the causes of disease.


More... [16.01.2006]

Unique agreement signed between the United Kingdom and Norway

Scientists from the ALSPAC study at the University of Bristol, the UK Biobank and Biobanks for Health at the Norwegian Institute of Public Health intend to collaborate in order to use their cohorts and biobanks in the most fruitful and efficient ways.


More... [23.01.2006]

Results from the legionnaires' disease outbreak

Saturday May 21th, the Østfold Hospital in Fredrikstad sent out a warning regarding an outbreak of legionnaires’ disease in Sarpsborg and Fredrikstad municipality in Southeast Norway. The municipality started immediately the work to find the source of the infection and The Norwegian Institute of Public Health (NIPH) has supported the work with a field epidemiologic group, expertise in water systems and microbiology testing. A total of 55 persons have been infected with legionella and among these ten have died.


More... [10.06.2005]

The Norwegian Mother and Child Cohort Study

The Norwegian Mother and Child Cohort Study (MoBa) is an ongoing pregnancy cohort study, with the aim of comprising 100 000 pregnancies by 2008. The study is based on questionnaires to the mother and father, and biological specimens are collected from mother, father and child. The main purpose of the study is to find causes of diseases. In the following pages you will find information especially intended for researchers who want to use the data for research but also for the participants in the MoBa study. The pages also contain list of references and research results of general interest.  


More... [21.03.2005]

Nordic Vaccine Meeting 2004

The Nordic Vaccine Meeting took place at Soria Moria Hotel and Conference Centre in Oslo in October 2004. Many of the presentations from the meeting are now available in pdf-format.


More... [23.11.2004]

Environmental causes of type 1 diabetes

The causes of type 1 diabetes are unknown. We know that persons with a specific genotype in the HLA-system have a significantly higher risk of the disease. About 2% of the population carry this genotype. About half of all persons with type 1 diabetes comes from this group. The risk of disease for people with the high-risk genotype, is about 6% up to 15 years of age.


More... [27.10.2003]